NCT01582295View on ClinicalTrials.gov

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

November 30, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

Cabozantinib

Starting dose 40 mg daily

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01582295 - XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease | Biotech Hunter | Biotech Hunter